Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BLESS trial of reduced-dose bleomycin in electrochemotherapy for cutaneous malignancies
2024-513360-25-00Phase 4Authorised
- Sponsor
- Region Zealand
- Start
- Oct 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of bleomycin in cutaneous malignancy, Subcutaneous malignant neoplasm and cutaneous metastases (2 arms), sponsored by Region Zealand. Primary endpoint: Clinical overall response rate at 3 months. Planned start Oct 2024; status: authorised.
02
Drugs
bleomycin
03
Conditions
cutaneous malignancySubcutaneous malignant neoplasmcutaneous metastases
Beyond the preview
Go deeper on 2024-513360-25-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-513360-25-00.